Patent ID: 6262077
Filing Date: 2001-07-17
Classification: A61K

Abstract:
A pharmaceutical composition comprising, in combination, a therapeutically effective amount of at least one neurokinin antagonist or a pharmaceutically acceptable derivative thereof, and a therapeutically effective amount of at least one inhibitor of 5-lipoxygenase or a pharmaceutically acceptable derivative thereof, wherein said neurokinin antagonist is a compound having the general formula: ##STR6##where B is OR.sub.2 ; NR.sub.6 COR.sub.2, CONR.sub.6 R.sub.7 or NR.sub.2 CONR.sub.6 R.sub.7,m=0 or 1,P is R.sub.5 -aryl; or R.sub.5 -heteroaryl; andY is H, CR.sub.2 R.sub.3 CO.sub.2 R.sub.6 ; CR.sub.2 R.sub.3 CONR.sub.6 R.sub.7 or CR.sub.2 R.sub.3 NR.sub.6 COR.sub.2 ;a=b=0, 1 or 2;Q has the same definitions as P above, with the proviso that P and Q may be the same or different;A is .dbd.N--OR.sub.1 ; .dbd.N--NR.sub.2 R.sub.3 ; or .dbd.CR.sub.1 R.sub.2 ;X is --O--; --NR.sub.6 --; --N(R.sub.6)CO--; or --CO--NR.sub.6 --;T is R.sub.4 -aryl; R.sub.4 -heteroaryl; R.sub.4 -cycloalkyl; or R.sub.2 -bridged cycloalkyl;R.sub.1 is H, C.sub.1 -C.sub.6 alkyl; or (CH.sub.2).sub.n --G where n=1-6,G is H; R.sub.4 -aryl; R.sub.4 -heteroaryl; COR.sub.6 ; CO.sub.2 R.sub.6 ; CONR.sub.6 R.sub.7 ; CN; OCOR.sub.6 ; SO.sub.3 R.sub.2 ; C(.dbd.NOR.sub.2)NR.sub.6 R.sub.7 ; C(.dbd.NR.sub.2)NR.sub.6 R.sub.7, with the proviso that when n.noteq.1, G can additionally be OR.sub.6, NR.sub.6 R.sub.7 or NR.sub.6 (CO)R.sub.7 ; R.sub.2 and R.sub.3 are independently H or C.sub.1 -C.sub.6 alkyl;R.sub.4 and R.sub.5 are independently 1, 2 or 3 substitutes independently selected from OR.sub.2,OC(O)R.sub.2, OC(O)NR.sub.6 R.sub.7, C.sub.1 -C.sub.6 alkyl, H halogen, CF.sub.3, C.sub.2 F.sub.5, or OCF.sub.3 ; andR.sub.6 and R.sub.7 are independently selected from H or C.sub.1 -C.sub.6 alkyl, with the proviso that when R.sub.6 and R.sub.7 are part of NR.sub.6 R.sub.7 then said NR.sub.6 R.sub.7 may form part of a C.sub.5 -C.sub.6 ring wherein 0-2 ring members are selected from the group consisting of --O--, --S-- and --NR.sub.2 --, with the further proviso that said C.sub.5 -C.sub.6 ring may contain substituents on said ring, with said substituents being selected from from the group consisting of hydrogen, halogen, --OR.sub.6 and --COOR.sub.6.